New ADHD medication on the horizon

Otsuka has announced the filing of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for centanafadine, once‐daily extended‐release capsules, a novel norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI), for the treatment of attention‐deficit hyperactivity disorder (ADHD) in children, adolescents, and adults. The NDA submission is supported by results from four pivotal Phase 3 clinical trials evaluating the efficacy and safety of centanafadine across patient populations.